Head and Neck Squamous Cell Carcinoma Market Segmentation:
Distribution Channel Segment Analysis
The hospital pharmacies segment is estimated to dominate 55% market share by 2035. The segment growth can be attributed to increasing number of cancer patients visiting the hospital for treatments, and therefore they need HNSCC drugs at the hospital premises. For instance, from 2015 to 2019, the number of cancer patients who visited the emergency department in Korea reached around 1,473,120. Nearly 55% of cancer-related ED visits ended in hospitalization, with 6% in ICU, and 10% died in the hospitals. On the other hand, several cancer treatment drugs are restricted for sale on online platforms or even to retail pharmacy outlets.
Drug Class Segment Analysis
The immunotherapy segment is expected to account for 60% share by 2035, led by significantly growing awareness among people regarding the effectiveness and advantages of cancer immunotherapy over chemotherapy. Furthermore, the surge in drug trials, coupled with the augmenting ratio of novel drugs approval from the authorities such as the FDA and EMA is estimated to drive the segment growth. For instance, Nivolumab (Opdivo) and Pembrolizumab (Keytruda), are two PD-L1 inhibitors, licensed for the treatment of patients with head and neck cancer. Whilst, Dostarlimab (Jemperli) is under phase II clinical trials for head and neck squamous cell carcinoma that has progressed or resurfaced.
On the other hand, the chemotherapy segment is projected to witness a notable CAGR during the forecast period, owing to rising adoption of chemotherapy along with radiation therapy amongst cancer patients worldwide. Moreover, the escalating usage of chemotherapy with the combination of other drugs and therapy has been delivering good outcomes.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Distribution Channel |
|
